(Approval lapsed) NYXOID naloxone 1.8mg nasal spray, solution in a single dose container (UK)
Section 19A approved medicine
(Approval lapsed) NYXOID naloxone 1.8mg nasal spray, solution in a single dose container (UK)
Section 19A approval holder
Mundipharma Pty Limited ABN 87 081 322 509
Phone
1800 188 009
Approved until
Status
Expired
Medicines in short supply/unavailable
NYXOID naloxone hydrochloride dihydrate 2.2 mg/actuation nasal spray vial - ARTG 309381
Indication(s)
Nyxoid is intended as part of the emergency treatment for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in: the home or other non-medical setting, a health facility setting. For this reason, Nyxoid should be carried by persons at risk of, or likely to witness such events. Nyxoid is indicated in adults and adolescents aged 14 years and over.